Sawai Lines Up Eight Launches In Japan
Forms Part Of Broader Strategy To Capture Japanese Market Share
Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.
You may also be interested in...
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.